Effect of Thyroidectomy on Tracheal Remodeling and Airway Physiology in Apparently Asymptomatic Patients with Goiter: A Prospective Study.

BACKGROUND: Tracheal airflow limitation is frequently reported in patients with goiter but is severely underestimated, and studies on how goiter and its treatment affect trachea are scarce. Moreover, the choice of the optimal treatment for individual patient with asymptomatic goiter is not straightforward. Therefore, in this study we aim to investigate the effect of goiter and subsequent thyroidectomy on tracheal anatomy and change in airflow in asymptomatic patient with goiter. METHODS: Seventy patients undergoing total/hemithyroidectomy (TT/HT) from Feb 2020 to Feb 2021 satisfying inclusion criteria were enrolled in the study. Neck radiograph (NR) and forced spirometry (FS) were performed preoperatively and on postoperative day 10 and 6 weeks and 3 months. RESULTS: Out of 70 patients, 84.3% patients were female, and mean duration and weight of goiter were 54.7 months and 72.21 gm, respectively. Of 70 patients, 57 were of benign pathology. Significant improvement in tracheal compression with moderate improvement in deviation was observed after surgery. Preoperative spirometry showed significant reduction in almost all parameters. After surgery, a weak improvement was observed at postoperative day 10 and 6 weeks; however, significant improvement in FEV1, PEFR, FEV1/FEV0.5, and FEF50%/FIF50% was observed at postoperative 3 months. Patient with right sided and those with ≥ 8 mm deviation were associated with poorer pulmonary function. Weak correlation was observed between neck NR and spirometry parameters. Weight of the thyroid gland significantly correlated with ratio of MVV/FEV1. CONCLUSION: Patients with asymptomatic goiter can have significant abnormal changes in airflow as evidenced by FS and NR. Thyroidectomy is followed by gradual restoration of tracheal deviation and compression with significant improvement in pulmonary airflow.

Revisiting Combination Chemotherapy as a Single Modality Palliative Therapy for Advanced Anaplastic Thyroid Carcinoma-a Single Institution Experience.

Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with dismal outcome especially in metastatic setting. Consensus for ideal treatment of advanced and metastatic ATC remains elusive. This study aimed to analyze the impact of palliative chemotherapy versus supportive care on overall survival in patients with metastatic anaplastic thyroid carcinoma. Patients diagnosed with ATC between the period January 2018 and December 2019 were prospectively followed. The patients opting for palliative chemotherapy received 3 weekly Paclitaxel (175 mg/m2) and Carboplatin (AUC-5). Out of the 31 patients diagnosed with ATC, clinicopathological profile of 29 patients was analyzed (2 patients who underwent upfront surgical resection with curative intent were excluded), out of which 20 patients were included in the survival analysis. The median age of presentation was 55.8 years with male:female ratio 1.9:1. Seventeen out of the total 29 patients presented with anaplastic transformation in long-standing goiter. Nineteen out of 20 (95%) patients presented with distant metastasis with lungs being the most common site. Nodal metastasis was present in all patients. Invasion of the strap muscles (90%) and trachea (80%) was the most common peri-thyroidal tissue invasion followed by invasion of the esophagus (40%), internal jugular vein (30%), and carotid artery (5%). Twelve out of the 20 patients opted for palliative chemotherapy. Overall, median survival from the time of diagnosis was 2.6 months, with median survival in patients receiving chemotherapy 3.1 months and those opting for supportive care 1.6 months (p=0.004). Out of all the factors analyzed, male sex (HR 6.521, 95% CI 1.143-37.206, p value 0.03) and vascular invasion (HR 0.066, 95% CI 0.009-0.499, p value 0.008) were poor prognostic indicators. Palliative chemotherapy showed increased survival benefit in patients with metastatic ATC. Male sex and vascular invasion were found to be significant factors associated with poor outcomes on Cox regression analysis.

PTH Gradient as a Predictor of Post Thyroidectomy Hypocalcemia.

BACKGROUND: Post thyroidectomy hypocalcemia is a common complication. Post thyroidectomy PTH estimation at varying cut offs and time have been used to predict hypocalcemia and aid in early and safe discharge. Single post thyroidectomy PTH values may be spuriously normal or high in a patient that subsequently develops unanticipated low calcium levels. This study aimed to evaluate the percentage change in preoperative and postoperative PTH (Gradient) in predicting post thyroidectomy hypocalcemia. METHODS: Forty-one patients of thyroidectomy had PTH preoperatively, postoperatively one-hour (PTH0) and day 1 (PTH1). PTH gradient was calculated as percentage change in postoperative PTH to preoperative (PTHG0, PTHG1). Hypocalcemia was categorized into mild or severe based on corrected calcium values and presence of clinical signs and/or symptoms of hypocalcemia. RESULTS: Ten (24.3%) and 11 (26.8%) patients had mild and severe hypocalcemia, respectively. PTHG0 and PTHG1 were significantly associated with risk for hypocalcemia (P-0.006 vs P-0.002). Higher PTH0 and PTH1 gradients were significantly associated with risk of hypocalcemia (PTH0 gradient OR-0.006, 95% CI 0.00-0.175, P-0.006; PTH1 gradient OR- 0.008, 95% CI 0.00-0.166, P-0.002). PTH0 gradient was the best predictor of hypocalcemia (AUC 0.855, SE-0.065, 95% CI0.710 to 0.945, P value <0.001) and PTH1 value was a better predictor of severe/clinical hypocalcemia (AUC 0.844, SE-0.072, 95% CI 0.697 to 0.938, P- value-0.001). Based on ROC, cutoffs of PTH0 gradient and PTH1 gradient for predicting hypocalcemia and severe/clinical hypocalcemia were taken as 60% and 75%, respectively (sensitivity 70%, specificity 90.5% for hypocalcemia; sensitivity 65%, specificity 90.9% for severe hypocalcemia). CONCLUSION: PTH gradient may be a better predictor of hypocalcemia and PTH1 gradient of >75% correlates with high risk of severe/clinical post thyroidectomy hypocalcemia.